simvastatin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Men, Y; Peng, H; Tang, J; Xie, R; Yang, W; Yao, X | 1 |
| Crown, J; Duffy, MJ; O'Grady, S | 1 |
| Czogalla, A; Filip-Psurska, B; Matusewicz, L; Podkalicka, J; Psurski, M; Sikorski, AF; Tabaczar, S; Wietrzyk, J; Ziółkowski, P | 1 |
| Jiang, L; Jiang, X; Kou, X; Lin, Z; Liu, H; Liu, L; Sun, F; Wang, X; Yang, Y | 1 |
| Boyer, O; Buquet, C; Castellanos-Esparza, YC; García Latorre, EA; Huang, L; Janin, A; Jiménez-Zamudio, LA; Li, H; Lu, H; Sanchez-Gonzalez, B; Shen, R; Vannier, JP; Varin, R; Wu, S | 1 |
| Fan, J; Feng, G; Han, J; Jiang, L; Jiang, X; Kou, X; Lin, Z; Liu, H; Sun, F; Wang, X; Yang, Y | 1 |
| Bai, F; Fan, L; Gao, X; Gong, J; Liu, F; Yu, Z | 1 |
| Brewer, T; Buchholz, TA; Debeb, BG; Hortobágyi, GN; Lacerda, L; Larson, R; Li, L; Liu, D; Masuda, H; Reddy, JP; Ueno, NT; Woodward, WA; Xu, W | 1 |
| Gollavilli, PN; Gopoju, R; Kanugula, AK; Karnewar, S; Kotamraju, S; Ummanni, R; Vasamsetti, SB | 1 |
| Bambhroliya, A; Bertucci, F; Birnbaum, D; Chu, K; Debeb, BG; Diagaradjan, P; Diehl, M; Finetti, P; Hittelman, W; Huang, X; Lacerda, L; Larson, R; Levental, I; Ruffell, B; Trenton, NJ; Ueno, NT; Van Laere, S; Wolfe, AR; Woodward, WA | 1 |
| Ahn, JS; Im, YH; Jung, HH; Kim, JY; Lee, SH; Park, YH | 1 |
| Chen, C; Deng, X; He, G; Rosol, TJ; Song, L; Yan, S; Yao, H | 1 |
1 review(s) available for simvastatin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Triple-negative breast cancer: is there a treatment on the horizon?
Topics: Anthracyclines; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Molecular Targeted Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Simvastatin; Taxoids; Triple Negative Breast Neoplasms | 2017 |
11 other study(ies) available for simvastatin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Simvastatin induced ferroptosis for triple-negative breast cancer therapy.
Topics: Animals; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Female; Ferroptosis; Humans; Magnetite Nanoparticles; Male; MCF-7 Cells; Mice, Nude; Signal Transduction; Simvastatin; Triple Negative Breast Neoplasms | 2021 |
Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Doxorubicin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2022 |
EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers.
Topics: Animals; Antineoplastic Agents, Immunological; Apoptosis; Cell Line, Tumor; Cetuximab; ErbB Receptors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liposomes; Mammary Neoplasms, Experimental; Mice, SCID; Simvastatin; Triple Negative Breast Neoplasms | 2019 |
Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation.
Topics: Animals; Apoptosis; Autophagosomes; Autophagy; Cell Line, Tumor; Cell Proliferation; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lysosomes; Mice; Protein Prenylation; rab GTP-Binding Proteins; rab7 GTP-Binding Proteins; Simvastatin; Triple Negative Breast Neoplasms; Vorinostat; Xenograft Model Antitumor Assays | 2017 |
Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Pentoxifylline; Simvastatin; Triple Negative Breast Neoplasms | 2018 |
Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.
Topics: Acetylation; Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Chaperonins; Female; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lysine; Mice; Mice, Inbred BALB C; Mice, Nude; Panobinostat; Protein Binding; Simvastatin; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p.
Topics: Cell Death; Cell Line, Tumor; Cholesterol; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MicroRNAs; Nuclear Respiratory Factor 1; Oxidative Stress; Simvastatin; Triple Negative Breast Neoplasms | 2019 |
Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.
Topics: Adult; Aged; Cell Differentiation; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Female; Humans; Inflammatory Breast Neoplasms; Kaplan-Meier Estimate; Mastectomy; MCF-7 Cells; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Proportional Hazards Models; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Simvastatin; Spheroids, Cellular; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2014 |
Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms.
Topics: Antigens, CD; Antineoplastic Agents; Antioxidants; Apoptosis; Biological Transport; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; Indoles; Iron; Mevalonic Acid; Nitric Oxide; Nitric Oxide Synthase Type II; Receptors, Transferrin; Simvastatin; Superoxide Dismutase; Transcription, Genetic; Triple Negative Breast Neoplasms | 2014 |
Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice, SCID; Middle Aged; Neoplasm Metastasis; Simvastatin; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Cell Survival; Chromones; Dual-Specificity Phosphatases; Female; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Phosphatases; Morpholines; Nitriles; Nuclear Proteins; Proto-Oncogene Mas; Proto-Oncogene Protein c-ets-1; RNA, Messenger; Simvastatin; Transcription Factors; Transfection; Triple Negative Breast Neoplasms; Tumor Stem Cell Assay | 2016 |